GnRH Antagonist

Phase 1

Amgen

GnRH Antagonist is one of 34 therapeutic programs targeting Prostate Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Prostate CancerRecruiting

Infertility (IVF Patients)Enrolling by invitation

Prostate CancerPhase 1

Recruiting

Infertility (IVF Patients)Preclinical

Enrolling by invitation

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

7 2

Antiandrogen Therapy

UUniversity of Washington

Phase 3

10 3

AAA817

Novartis

Phase 3

1 4

Androgen Deprivation Treatment

MMedical University of Vienna

Phase 3

1 5

HC-1119

HHinova Pharmaceuticals Inc.

Phase 3

2 6

Antibiotic Prophylaxis

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 7

Trexall

Jazz Pharmaceuticals

Preclinical

—8

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

1 9

Duragesic

CCephalon

Preclinical

1 10

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalRecruiting

Endometrial Neoplasms

NCT06379113

Q1 2030

Phase 1Recruiting

Prostate Cancer

NCT06613100

Clinical

Trials by Indication[1]

Endometrial Neoplasms1 trial

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole in Obese Progestin-insensitive Early-stage Endometrial Cancer Patients With Conservative Treatment

Recruiting·XXiaojun Chen·Preclinical·NCT06379113·29 enrolled

Infertility (IVF Patients)1 trial

Prospective Randomized Single-Blind Study of the Effectiveness of the Superovulation Stimulation Protocol Using hCG Compared to Standard Protocols With Different Gonadotropin Doses in In Vitro Fertilization Programs

Enrolling by invitation·LLTD "EKODNIPRO", Medical centre Medical Plaza Dnipro·Preclinical·NCT07771283·360 enrolled

Prostate Cancer1 trial

A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, and Feasibility of Neoadjuvant Xaluritamig Therapy Prior to Radical Prostatectomy in Subjects With Newly Diagnosed Localized Intermediate or High-Risk Prostate Cancer

Recruiting· Amgen logo

Amgen·Phase 1·NCT06613100·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for GnRH Antagonist. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for GnRH Antagonist. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Amgen

GnRH Antagonist

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q1 2030

Trials by Indication[1]

Endometrial Neoplasms1 trial

Infertility (IVF Patients)1 trial

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News